Kulasekararaj, A., Sicre-de-Fontbrune, F., Gaya, A., Weitz, I., Kuter, D., Araten, D., Patel, B., Singh, A., Kelly, R., Bona, E. D., Loschi, M., Pullarkat, V., Schubert, J., Vannucchi, A. M., Yenerel, M., Latour, R. P. D., Mahajan, N., Monaco, L., Ding, T., Lawniczek, T., Ferber, P., Dahlke, M., Risitano, A. (2025). Oral iptacopan monotherapy demonstrates clinically meaningful hemoglobin increases in patients with paroxysmal nocturnal hemoglobinuria with baseline hemoglobin levels 10 to <12 g/dl on anti-C5 therapy: Subgroup analysis of the appulse-pnh Phase 3b trial. Blood. https://doi.org/10.1182/blood-2025-4981